期刊文献+

进展期胃癌新辅助化疗临床疗效分析

原文传递
导出
摘要 目的评估进展期胃癌患者新辅助化疗后手术的临床疗效。方法选择进展期胃癌患者64例分为常规手术组(32例)和新辅助化疗+手术组(32例),新辅助化疗+手术组患者进行2个周期的新辅助化疗,行CT复查,再进行手术治疗。结果常规手术组肿瘤切除率为84.4%(27/32),根治性切除率为43.8%(14/32),剖腹探查率为15.6%(5/32);新辅助化疗+手术组肿瘤切除率为93.8%(30/32)。根治性切除率为68.8%(22/32),剖腹探查率为6.3%(2/32)。两组均无手术死亡病例,并发症发生率差异无显著性。结论进展期胃癌患者在新辅助化疗后,进行手术治疗,可以提高手术根治率和切除率。
作者 王世东
机构地区 河南省中医院
出处 《医药论坛杂志》 2009年第10期58-59,共2页 Journal of Medical Forum
  • 相关文献

参考文献5

  • 1Ajani JA, Mansfield PF,Janjan N, et al. Multi -institutional trial of preopcrative chemoradiotherapy in patients with potentially respactable gastric carcinoma [ J ], J Clin Oncol, 2004,22(14) :2 774-2 780
  • 2季加孚.胃癌外科的现状与发展趋势[J].中国普外基础与临床杂志,2006,13(1):1-3. 被引量:65
  • 3Persiani R, D Ugo D, Biondi A, et al. Down staging after neoadiuvant chemotherapy in locally advanced gastric carcinoma [ J ]. Suppl Tumofi ,2005,4 (3) : S88
  • 4季加孚,武爱文.进展期胃癌新辅助化疗的研究进展[J].中华胃肠外科杂志,2007,10(4):394-395. 被引量:58
  • 5Fujitani K, Ajani JA, Crane CH, et al. Impact of induction chemothearpy and peropeartive chemoadriothearpy on opeartive morbidity and moartlity inpatients with locoergional adencoacrinma of the stomach or gastroesphageal junction [ J ]. Ann Surg Oncol, 2007,14 (7) : 2 010-2 017

二级参考文献13

  • 1Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001,345 : 725-730.
  • 2Satoh S, Hasegawa S, Ozaki N, et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer, 2006,9: 129-135.
  • 3D'Ugo D, Persiani R, Rausei S, et al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol, 2006,32: 1105-1109.
  • 4Ajani JA, Winter K, Okawara GS, et al. Phase Ⅱ trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol, 2006,24: 3953- 3958.
  • 5Brenner B, Shah MA, Karpeh MS, et al. A phase Ⅱ trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol, 2006, 17 : 1404-1411.
  • 6Newman E, Potmesil M, Ryan T, et al. Neoadjuvant chemotherapy,surgery,and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophagcal junction carcinoma:a phase Ⅱ study. Semin Oncol, 2005,32 (6 Suppl 9):S97-100.
  • 7Nakagawa S, Nashimoto A, Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. Gastric Cancer.
  • 8Fink U, Ott K, Weber W, et al. Neoadjuvant therapeutic principles guided by response prediction and evaluation. Kongressbd Dtsch Ges Chir Kongr, 2002, 119: 829-833.
  • 9Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol, 2006,24:4692-4695.
  • 10Napieralski R, Ott K, Kremer M, et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res, 2005,11 : 3025-3031.

共引文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部